

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Ezban et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: January 14, 2002

Examiner: To be assigned

For: Use of FVIIa or a Tissue Factor Antagonist for Regulating Gene Expression and Cell Migration or Chemotaxis

**PRELIMINARY AMENDMENT**

Commissioner for Patents  
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested:

**IN THE CLAIMS:**


Please cancel claims 1-16 without prejudice or disclaimer.

**REMARKS**

Entry of this amendment is respectfully requested. In this amendment, claims 1-16 are cancelled without prejudice. No new matter is added. Accordingly, claims 17-22 are pending and at issue. It is believed that the claims are in condition for allowance, and a determination to that effect is earnestly solicited.

Respectfully submitted,

Date: January 14, 2002

  
Reza Green, Reg. No. 38,475  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650

PATENT TRADEMARK OFFICE